Suchergebnisse - "Cantini, Fabrizio"

PubPharm (38)

1

Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis : 2021 updated ITABIO statements

enthalten in: Expert opinion on drug safety | 2022

von Cantini, F. | Goletti, D. | Benucci, M. | +3

2

Quality of life and therapeutic management of axial spondyloarthritis patients in Italy : a 12-month prospective observational study

enthalten in: Clinical and experimental rheumatology | 2021

von D'Angelo, S. | Malavolta, N. | Scambi, C. | +21

3

COVID-19 epidemiology in rheumatic diseases in Tuscany : A case-control study

enthalten in: Joint bone spine | 2021

von Francesconi, P. | Cantini, F. | Profili, F. | +3

4

Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases

enthalten in: Expert opinion on drug safety | 2020

von Cantini, F. | Blandizzi, C. | Niccoli, L. | +2

5

The Nocebo Effect in Rheumatology : An Unexplored Issue

enthalten in: The Israel Medical Association journal : IMAJ | 2020

von Cantini, F. | Niccoli, L. | Franchi, G. | +2

6

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4 : possible fallout on non-medical switching

enthalten in: Annals of the rheumatic diseases | 2020

von Cantini, F. | Benucci, M.

CommentOn: Ann Rheum Dis. 2019 Feb;78(2):192-200. - PMID 30396903

7

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice

enthalten in: Expert opinion on drug safety | 2019

von Cantini, F. | Niccoli, L. | Capone, A. | +2

8

Additional comment to : 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Scherlinger and Schaeverbeke

enthalten in: Annals of the rheumatic diseases | 2019

von Cantini, F. | Benucci, M.

CommentOn: Ann Rheum Dis. 2018 Feb;77(2):165-174. - PMID 28866648

9

Switching from the bio-originators to biosimilar : is it premature to recommend this procedure?

enthalten in: Annals of the rheumatic diseases | 2019

von Cantini, F. | Benucci, M.

CommentOn: Ann Rheum Dis. 2018 Feb;77(2):165-174. - PMID 28866648

10

Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs

enthalten in: Expert review of anti-infective therapy | 2018

von Goletti, D. | Petrone, L. | Ippolito, G. | +3